Moreover, a subgroup of MS patients with high peripheral blood type I IFN signature, was found to be refractory to exogenous administration of recombinant IFN-β (Comabella et al., 2009), a well-established MS treatment (Author anonymous, 1993; Kieseier, 2011). This evidence concerns the gene IFNB1 and myeloid sarcoma.